Wordt geladen...
Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
BACKGROUND: Anaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with a median survival of 3–5 months. The BRAF oncogene is mutated to its active form in up to 24% of ATC cases. Sorafenib is a tyrosine kinase inhibitor that acts on the RAF-1 serine/threonine kinase. In preclini...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Mary Ann Liebert, Inc.
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3643255/ https://ncbi.nlm.nih.gov/pubmed/23113752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2012.0103 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|